Genfit (OTC: GNFTF)
Genfit Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Genfit Company Info
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.
News & Analysis
Better Buy: Intercept Pharmaceuticals vs. Genfit
Which stock wins in a battle between these two liver-disease-focused biotechs?
Could a Diagnostic Be Key to Winning This Big Healthcare Market?
A small company is working on new ways to tackle a life-threatening liver disease.
Can This Tiny Biotech Revolutionize a $35 Billion Market?
This upstart is developing a diagnostic test and treatment for nonalcoholic steatohepatitis, or NASH, an increasingly common liver disease.
4 Top Stocks for Investing in Pharma's Next $35 Billion Market
A NASH dash is on -- and these drugmakers could come out on top.
Should Gilead Sciences Be Worried About Allergan?
Gilead Sciences might want to pay attention to Allergan's aggressive expansion of its NASH program.
Could These 2 Small Biotechs Beat Allergan and Gilead Sciences?
Genfit and Intercept could be on track to beat bigger players Allergan and Gilead in the potentially lucrative NASH market.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.